WO2005097113A3 - Antagonistes du recepteur de la 5-ht2b - Google Patents

Antagonistes du recepteur de la 5-ht2b Download PDF

Info

Publication number
WO2005097113A3
WO2005097113A3 PCT/GB2005/001378 GB2005001378W WO2005097113A3 WO 2005097113 A3 WO2005097113 A3 WO 2005097113A3 GB 2005001378 W GB2005001378 W GB 2005001378W WO 2005097113 A3 WO2005097113 A3 WO 2005097113A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
receptor antagonists
cycloalkyl
independently selected
Prior art date
Application number
PCT/GB2005/001378
Other languages
English (en)
Other versions
WO2005097113A2 (fr
Inventor
Richard Anthony Borman
Robert Alexander Coleman
Original Assignee
Pharmagene Lab Ltd
Richard Anthony Borman
Robert Alexander Coleman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408064A external-priority patent/GB0408064D0/en
Priority claimed from GB0408062A external-priority patent/GB0408062D0/en
Application filed by Pharmagene Lab Ltd, Richard Anthony Borman, Robert Alexander Coleman filed Critical Pharmagene Lab Ltd
Publication of WO2005097113A2 publication Critical patent/WO2005097113A2/fr
Publication of WO2005097113A3 publication Critical patent/WO2005097113A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'utilisation d'un composé représenté par la formule (Ia) ou d'un sel pharmaceutiquement acceptable de celui-ci dans la fabrication d'un médicament servant au traitement d'une sensibilité viscérale accrue ou d'une douleur viscérale. Dans cette formule, R1 ou R4 est sélectionné dans un groupe comprenant H et C1-6 alkyle, C3-7 cycloalkyle, C3-7 cycloalkyle-C1-4 alkyle et phényle-C1-4 alkyle éventuellement substitués, tandis que le R1 ou R4 restant désigne un groupe C9-14 aryle éventuellement substitué; R2 et R3 soit (i) sont sélectionnés indépendamment parmi H, R, R', SO2R, C(=O)R, (CH2)nNR5R6, n étant compris entre 1 et 4, et R5 et R6 étant sélectionnés indépendamment parmi H et R, R désignant C1-4 alkyle éventuellement substitué et R' désignant phényle-C1-4 alkyle éventuellement substitué; soit (ii) forment, avec l'atome d'azote auquel ils sont liés, un groupe hétérocyclique C5-7 éventuellement substitué.
PCT/GB2005/001378 2004-04-08 2005-04-08 Antagonistes du recepteur de la 5-ht2b WO2005097113A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0408064A GB0408064D0 (en) 2004-04-08 2004-04-08 5-HT2B receptor antagonists
GB0408062.8 2004-04-08
GB0408064.4 2004-04-08
GB0408062A GB0408062D0 (en) 2004-04-08 2004-04-08 5-HT2B receptor antagonists

Publications (2)

Publication Number Publication Date
WO2005097113A2 WO2005097113A2 (fr) 2005-10-20
WO2005097113A3 true WO2005097113A3 (fr) 2006-10-12

Family

ID=34978881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/001378 WO2005097113A2 (fr) 2004-04-08 2005-04-08 Antagonistes du recepteur de la 5-ht2b

Country Status (1)

Country Link
WO (1) WO2005097113A2 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008668A2 (fr) * 1999-07-30 2001-02-08 Pharmagene Laboratories Ltd Utilisation de 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine pour le traitement des troubles gastro-intestinaux
WO2001014372A2 (fr) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Agent promoteur de la production/secretion de neurotrophine
WO2003068226A1 (fr) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 2-oxazolamines et leur utilisation comme antagonistes du recepteur 5-ht2b
WO2003068227A1 (fr) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited Antagonistes du recepteur 5-ht2b
WO2004009016A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Compositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
WO2004009017A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004094395A2 (fr) * 2003-04-18 2004-11-04 Merck & Co., Inc. Thiazoles, oxazoles et imidazoles a substitution biaryle utilises comme bloqueurs du canal sodique
WO2005012263A1 (fr) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited Antagonistes du recepteur 5-ht2b

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008668A2 (fr) * 1999-07-30 2001-02-08 Pharmagene Laboratories Ltd Utilisation de 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine pour le traitement des troubles gastro-intestinaux
WO2001014372A2 (fr) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Agent promoteur de la production/secretion de neurotrophine
WO2003068226A1 (fr) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 2-oxazolamines et leur utilisation comme antagonistes du recepteur 5-ht2b
WO2003068227A1 (fr) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited Antagonistes du recepteur 5-ht2b
WO2004009016A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Compositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
WO2004009017A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004094395A2 (fr) * 2003-04-18 2004-11-04 Merck & Co., Inc. Thiazoles, oxazoles et imidazoles a substitution biaryle utilises comme bloqueurs du canal sodique
WO2005012263A1 (fr) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited Antagonistes du recepteur 5-ht2b

Also Published As

Publication number Publication date
WO2005097113A2 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
RU2005110061A (ru) Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
JP2004527515A5 (fr)
EP2228064A3 (fr) Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
CA2481482A1 (fr) Derives de tropane utilises comme modulateur as de ccr5
EP1679309A4 (fr) Medicament antistress et usage medical correspondant
EP1669352A4 (fr) Derive thiazoline et utilisation
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
EP2423207A3 (fr) Derives de pyrimidone substitues en position 2 par une amine cyclique en tant qu'inhibiteurs de TPK1
RU2004109812A (ru) Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
GEP20115322B (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EP1839662A4 (fr) Agent antitumoral
MEP0408A (xx) Derivati hinociklicnog hinazolina kao inhibitori pde7
CA2728098A1 (fr) Composes tricycliques contenant du pyrazole en tant qu'antagonistes du recepteur ep1
WO2007125398A3 (fr) Sulfonamides
EP1857459A3 (fr) Composé pyrazolopyrimidine et son procédé de fabrication
WO2007070865A3 (fr) Composes innovants
WO2006103544A3 (fr) Composes thieno[2,3-d]pyrimidine
WO2006029210A3 (fr) 1,3-diamines acycliques et leurs utilisations
JP2008501662A5 (fr)
WO2006036007A3 (fr) Preparation a liberation modifiee

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase